Make Better Decisions

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Merck
Cerilliant
Cipla
Dow
McKinsey
Novartis
Citi
Fish and Richardson
Queensland Health

Generated: January 18, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,985,418

« Back to Dashboard

Which drugs does patent 7,985,418 protect, and when does it expire?

Patent 7,985,418 protects RENVELA and is included in one NDA.

This patent has seventeen patent family members in fifteen countries.
Summary for Patent: 7,985,418
Title:Aliphatic amine polymer salts for tableting
Abstract: The tablets, compositions and methods of the present invention, comprising a carbonate salt of an aliphatic amine polymer and s monovalent anion can prevent or ameliorate acidosis, in particular acidosis in patients with renal disease. The tablets and compositions of the present invention maintain a disintegration time of no greater than 30 minutes at 37.degree. C. and at pH of at least 1 for a period of at least ten weeks at 60.degree. C. Furthermore, the tablets are stable for extended periods of time without the need for specialized storage conditions.
Inventor(s): Bhagat; Hitesh R. (Wayland, MA), Goldberg; Jeffrey M. (Framingham, MA), Harianawala; Abizer I. (Lexington, MA), Brenner; Louis (Brookline, MA)
Assignee: Genzyme Corporation (Cambridge, MA)
Application Number:11/262,291
Patent Claim Types:
see list of patent claims
Dosage form; Composition;

Drugs Protected by US Patent 7,985,418

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Genzyme RENVELA sevelamer carbonate TABLET;ORAL 022127-001 Oct 19, 2007 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,985,418

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,808,738 Aliphatic amine polymer salts for tableting ➤ Subscribe
9,555,056 Aliphatic amine polymer salts for tableting ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,985,418

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Japan 5758945 ➤ Subscribe
Japan 2008518950 ➤ Subscribe
Croatia P20170505 ➤ Subscribe
Hong Kong 1113543 ➤ Subscribe
Spain 2621553 ➤ Subscribe
European Patent Office 3167878 ➤ Subscribe
European Patent Office 1807057 ➤ Subscribe
Japan 2013139480 ➤ Subscribe
Japan 5307398 ➤ Subscribe
Denmark 1807057 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Farmers Insurance
Daiichi Sankyo
Julphar
McKesson
Colorcon
Mallinckrodt
Johnson and Johnson
Argus Health
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot